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summary
Patients with rheumatoid arthritis (RA) are frequently afflicted by pain, which may be caused by joint in-
flammation (leading to structural joint damage) or secondary osteoarthritis, and may be increased by central 
sensitisation. Non-inflammatory pain may also confuse the assessment of disease activity, and so the aim of 
treatment is not only to combat inflammatory disease, but also relieve painful symptoms. In order to ensure 
effective treatment stratification, it is necessary to record a patients medical history in detail, perform a physical 
examination, and objectively assess synovitis and joint damage. The management of pain requires various ap-
proaches that include pharmacological analgesia and biological and non-biological treatments. Although joint 
replacement surgery can significantly improve RA-related pain, it may only be available to patients with the 
most severe advanced disease.
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n	 INTRODUCTION
Rheumatoid arthritis (RA) is a common inflammatory joint disease that has a 
major impact on the quality of life, work-
ing productivity, and the use of healthcare 
resources (1, 2). RA patients usually de-
clare that pain is their greatest problem 
and highest priority (3-5) as it causes psy-
chological distress and sleep disturbances, 
and may even be a more important cause 
of disability than structural joint dam-
age (6, 7). Pain is frequently considered 
a marker of inflammation, but there is 
only a weak correlation between the in-
tensity of pain and measures of peripheral 
inflammation(8, 9); however, pain is as-
sociated with disease activity, and radio-
graphic changes may be linked to future 
pain (10-13). 
Inflammation causes pain, stiffness and 
progressive joint damage, but it is becom-
ing increasingly possible to suppress it 
completely and ensure clinical remission 
(14), and long-term outcomes may be im-
proved if this is rapidly achieved (15, 16). 
The results of clinical trials indicate that 
early intensive treatment with disease-
modifying modifying anti-inflammatory 
drugs (DMARDs) and corticosteroids lead 
to better pain outcomes (17-20), especial-
ly when guided by the regular monitoring 
of disease activity. The effective suppres-
sion of inflammatory disease during the 
first years after a diagnosis of RA tends 
to decrease the level of pain, although it 
often does not completely disappear (21-
24), and may subsequently increase once 
again.
The pain associated with RA may oc-
cur spontaneously or be evoked by gently 
moving a joint within its normal working 
range, and may even be felt in the appar-
ently normal surrounding tissue. Referred 
pain syndromes have also been reported 
because the entity of symptoms does not 
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necessarily correlate with the severity of 
the underlying disease, and symptoms may 
continue even in the absence of disease ex-
acerbations (25, 26).
RA-related pain may be worsened by joint 
damage, which may be secondary to in-
flammatory disease or due to concomitant 
osteoarthritis (OA). Moreover, the preva-
lence of chronic, non-inflammatory pain 
syndromes such as fibromyalgia (FM) is 
higher among patients with RA than in the 
general population (27, 28). Patients with 
inflammatory arthritis and FM have higher 
levels of disease activity and a poorer qual-
ity of life than their counterparts without 
FM. Pain therefore not only affects patients 
directly, but also indirectly contributes to 
the psychological and social impact of RA, 
and the need for better analgesia remains 
an important issue (1, 2).
n	 PaIN MeChaNIsMs IN Ra
Causes of RA pain may vary between early 
and late disease, during and between in-
flammatory flares, and between different 
individuals.The inflamed synovium gener-
ates mediators such as prostaglandins and 
bradykinin and proinflammatory cytokines 
such as tumor necrosis factor alfa (TNF-α), 
interleukin-1 (IL-1), and IL-6 and nerve 
growth factor beta (NGF-β) which sensi-
tize peripheral nerves contributing signifi-
cantly to the generation and maintenance 
of pain (29-32). 
The synovium is unlikely to be the only 
source of pain in RA, and sensory nerves 
are also localized to joint capsule, liga-
ments, the outer regions of menisci, sub-
chondral bone, tendon sheaths, and mus-
cles (29). 
Articular cartilage and the inner two-thirds 
of the menisci are normally aneural, per-
mitting normal pain-free weight bearing 
and joint movement. 
Synovitis is associated with altered ex-
pression of neurotransmitters, such as 
γ-aminobutyric acid (GABA), substance 
P and calcitonin gene-related peptide 
(CGRP), and their corresponding receptors 
in the spinal cord (33, 34). Microglia and 
astrocytes within the spinal cord are acti-
vated to produce cytokines such as TNF-α, 
IL-1, and IL-6, which in turn facilitate pain 
transmission (35, 36). Enhanced descend-
ing activation and reduced descending in-
hibition may further increase nociceptive 
transmission (37-39). 
Central sensitization may be more wide-
spread than the innervation of the inflamed 
joint, resulting in reduced pain thresholds 
in adjacent tissues (1, 2, 40). 
Widespread reductions in pain pressure 
thresholds have been associated with low 
mood and sleep disturbance (41, 42), fea-
tures shared with FM. Indeed, approxi-
mately 8% of patients with RA may satisfy 
classification criteria for FM in cross-sec-
tional surveys (43, 44). Application of FM 
classification criteria in RA may identify 
a subgroup of patients with the most ab-
normal pain processing, but may conceal a 
larger number of patients in whom similar 
pain mechanisms make an important con-
tribution to their symptoms.
Pain in RA may be further exacerbated by 
joint damage, either secondary to inflam-
matory disease, or because of comorbid 
OA. This may be the case particularly in 
long-established disease. 
RA structural changes (erosions and joint 
space narrowing) are associated with great-
er pain, although they may explain only 2% 
of pain intensity after adjustment for other 
factors such as current disease activity (45). 
Psychological factors contribute to the pain 
experience, and in addition, pain itself im-
poses a psychological burden. Psychologi-
cal factors influence pain reporting in RA 
(46, 47), and high depression indices have 
been associated with greater RA pain (48). 
The pain experience may be modified by 
beliefs about its causes and consequences, 
and expectations about prognosis and re-
sponse to treatment. 
The pain experience is complex and multi-
faceted, comprising both sensory and emo-
tional components. 
Despite the undoubted contribution of in-
flammation to RA pain, persistent pain 
despite adequate control of inflammation 
indicates contributions from multiple pain 
mechanisms (1, 2).
No
n-
co
mm
er
cia
l u
se
 n
ly
review
20 Reumatismo 1/2014
P. Sarzi-Puttini, F. Salaffi, M. Di Franco et al.
n	 ClINICal exPRessION  
 Of PaIN IN Ra
Pain is a major risk factor for a poor out-
come. Patients with early RA who report 
high levels of bodily pain at the time of 
presentation are more likely to report 
greater disability after one year (49). Pa-
tients describe the severity, quality and 
periodicity of their joint pain in different 
ways. It is often described as “gnawing” or 
aching, which suggest nociceptive mecha-
nisms directly mediated by inflammation 
or joint damage, but other descriptors such 
as “burning” or “shooting” are more char-
acteristic of neuropathic pain and suggest 
possible nerve damage. Finally, the fre-
quent descriptions of the more widespread 
pain associated with sleep disturbances, 
fatigue and mood (50) suggest abnormal 
central pain processing.
The 28-joint Disease Activity Score 
(DAS28) is frequently used to assess joint 
inflammation in randomised controlled 
trials (RCTs) and to guide treatment de-
cisions in clinical practice (51). Intensive 
‘treat-to-target’ regimens require treatment 
escalation in patients with active disease 
defined by their DAS28, and some nation-
al guidelines (such as those of the United 
Kingdom) restrict the use of biological to 
patients with a high score. However, the 
relationship between DAS28 and inflam-
matory disease activity is confounded by 
other factors (52). Although visual ana-
logue scales (VAS) and tender joint counts 
certainly increase with inflammation, and 
are both closely related with reported bod-
ily pain (53), they may also be increased 
by concomitant painful conditions such as 
OA, which usually affects the hands and 
knees (joints included in the DAS28), or by 
changes in pain processing such as central 
sensitisation, which coincides with joint 
inflammation and may make it difficult 
to interpret the DAS28 (54). For example, 
patients who fulfil the diagnostic criteria 
for both RA and FM report higher levels 
of pain (55) and have a higher DAS28 (56) 
than those with RA alone, which may indi-
cate that central sensitisation or a painful 
comorbidity affects the scoring.
Two recent studies have found that pain 
significantly affects patients’ assessments 
of RA disease activity. The first involved 
7,028 patients from the Quantitative 
Standard Monitoring of Patients with RA 
(QUEST-RA) database receiving “usual 
care” at 83 centres in 30 countries (57), 
and showed that pain was the single most 
important determinant of patient global 
assessment. The second involved 646 
RA patients starting methotrexate (MTX) 
treatment at an academic outpatient clinic, 
and found that pain explained 75.6% of 
the variability patient global assessment 
scores (58).
Although pain contributes less to physi-
cian global assessments, it was the fourth 
most important determinant of the physi-
cian global assessment in the QUEST-RA 
study, after swollen joint counts, the eryth-
rocyte sedimentation rate, and tender joint 
counts (57), and second only to swollen 
joint counts in the physician global assess-
ment of the MTX study (58), The fact that 
it was also one of the most significantly 
discordant variables between the patient 
and physician global assessments in both 
studies further underlines the importance 
of pain to patients and suggests that it is 
insufficiently considered by physicians.
n	 PhaRMaCOlOgICal  
 MaNageMeNT  
 Of Ra-RelaTeD PaIN 
The 3e (evidence, expertise, exchange) ini-
tiative, a 17-country collaborative project 
that promotes evidence-based practice in 
rheumatology, has recently published rec-
ommendations for the pharmacological 
management of pain in patients with in-
flammatory arthritis (59), many of which 
were based on a series of Cochrane data-
base systematic reviews published in 2011-
2012. 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) are used to manage pain in RA 
patients, but are not appropriate for long-
term disease control (60, 61); furthermore, 
although the early use of DMARDs is very 
important (62, 83), the significance of pain 
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to the patients means that they often take 
analgesics from the start of the disease. Ac-
cording to the European League Against 
Rheumatism (EULAR), symptomatic 
patients presenting with early arthritis 
should be treated with NSAIDs after their 
gastrointestinal, renal, and cardiovascular 
status has been carefully evaluated (64), 
whereas the British Society for Rheuma-
tology (BSR) guideline for the long-term 
management of RA recommends the short-
term use of a stepped approach combining 
NSAIDs with a proton pump inhibitor (64), 
and the National Institute for Health and 
Care Excellence (NICE) guideline sug-
gests analgesics (e.g. paracetamol, codeine 
or fixed-dose combinations) as a means of 
reducing the need for long-term NSAID or 
cyclo-oxygenase (COX)-2 inhibitor treat-
ment (64). 
However, the use of analgesics in RA is 
often only indirectly supported as the evi-
dence comes from RCTs involving patients 
with other conditions, and publication bi-
ases may conceal some findings of inef-
ficacy in arthritis. Furthermore, although 
paracetamol is readily available, there is 
little RCT-based evidence supporting its 
use (65-69), and the trials have often used 
it in combination with another analgesic 
of a different class. Paracetamol is often a 
component of combined products, and one 
potential concern is that they may mask the 
patient’s cumulative paracetamol intake, 
which should not exceed four grams in 
healthy adults. On the other hand, typical 
paracetamol-containing products include 
opioid combinations (codeine, tramadol, 
oxycodone, etc.), which may actually be 
opioid sparing because they provide effec-
tive analgesia at lower opioid doses than 
single opioids (89), and it has been demon-
strated that the fixed-dose combination of 
tramadol and paracetamol leads to syner-
gistic benefits (70, 71).
Nevertheless, it does seem to offer some 
short-term analgesic benefit and, in combi-
nation with a COX inhibitor, may be more 
effective than either alone, although there 
is no evidence that this maintained in the 
long term.
A systematic review (72) of 11 randomised 
or quasi-RCTs comparing opioids with 
placebo or an active analgesic has con-
cluded that the evidence in favour of the 
use of weak opioids (codeine, dextro-
propoxyphene, pentazosine, tilidine and 
tramadol) is itself weak. Furthermore, the 
risk ratio for study withdrawal due to the 
frequent side effects of constipation, diz-
ziness, nausea and vomiting between the 
opioid- and placebo-treated participants 
was 2.7, and the use of opioids may also 
lead to opioid-induced hyperalgesia, which 
is associated with heightened pain sensi-
tivity and increased clinical pain intensity. 
Consequently, it is generally recommended 
that long-term opioid prescriptions should 
be minimised and, when opioids are neces-
sary, their use should be regularly and care-
fully monitored (73-78).
A Cochrane systematic review found that 
the evidence in favour of using neuro-
modulators to treat RA-related pain was 
also weak (79), although it only considered 
four small randomised, placebo-controlled 
trials: two of nefopam (a centrally acting 
analgesic used in Europe but not the United 
States), one of topical capsaicin, and one 
of oro-mucosal cannabis. The authors con-
cluded that topical capsaicin could be con-
sidered as adjuvant therapy for RA-related 
pain (80). Other potential adjuvant treat-
ments options for pain in inflammatory 
arthritis recommended by the 3e initiative 
are gabapentin and pregabalin, although 
it should be remembered that these rec-
ommendations are mainly based on their 
efficacy in studies of pain in FM, a non-
inflammatory, chronic widespread pain 
condition (81, 82).
Biological therapies (83-85), are reserved 
for patients with the most advanced or se-
vere disease, whereas disease control in the 
majority of patients depends on glucocorti-
costeroids and traditional DMARDs such 
as MTX (86, 87). Glucocorticosteroids and 
DMARDs reduce RA-related pain, but the 
analgesic effects of the former may only 
last for three months (88, 89). The early 
suppression of inflammatory disease ac-
tivity is not only important to reduce pain 
in the short term because delaying the in-
troduction of DMARDs is associated with 
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worse pain 12 months after presentation. 
Finally, DMARD combinations may be 
more effective than monotherapy 
It must also be remembered that inflamma-
tion is only one component contributing to 
the pain experienced by many arthritic pa-
tients, and incomplete symptomatic relief is 
frequent even when there is other evidence 
of inflammatory control such a reductions 
in swollen joint counts, the levels of acute-
phase reactants, and ultrasound findings of 
synovitis. These clinical observations and 
the often slow action of disease-modifying 
treatments mean that alternative strategies 
are necessary. Although adequate analgesia 
may have a positive effect on disease activ-
ity scores by reducing joint tenderness and 
improving patient-reported general health, 
it is necessary not to mistake this for the 
suppression of the underlying disease.
Tricyclic antidepressants (TCAs such as 
amitriptyline, dothiepin and imipramine) 
inhibit serotonin and norepinephrine reup-
take and neuronal sodium channels (90), 
but it is believed that the differences in the 
antinociceptive effects of the various TCAs 
are substantially due their non-serotoniner-
gic properties. The results of clinical trials 
of TCAs have led to equivocal results in 
RA patients (91). A Cochrane systematic 
review of eight RCTs comparing antide-
pressant therapy with placebo or an active 
intervention found insufficient evidence to 
recommend its use to treat RA-related pain 
(91), whereas the 3e recommendations in-
clude TCAs as a potential adjuvant treat-
ment for patients with inflammatory arthri-
tis (59), although it was specifically noted 
that the still-incomplete data mean that 
they should only be considered for a subset 
of patients. Nevertheless, TCAs offer RA 
patients significantly more pain relief than 
placebo (91-93), and their use has become 
so widespread that it has been proposed 
that, like anticonvulsants, they should be 
considered “pain-modifying drugs” . 
The current stratification of analgesic treat-
ment is based on potency or sequential tri-
als, beginning with the least expensive, 
low- risk treatments. However, individual 
failures of analgesic or anti-inflammatory 
therapy may indicate that other pain mech-
anisms are involved, and that patients may 
benefit more if stratified care is based on 
the careful evaluation of the contributions 
of inflammation, joint damage and central 
sensitisation. 
The multi-dimensional nature of RA and 
most other chronic pain indications sug-
gests that a combined approach to anal-
gesia may be more appropriate, and find-
ings of the 23 studies published so far have 
been summarised in a recent Cochrane 
systematic review (94). No meta-analysis 
was made because of the heterogeneity of 
these studies, but 18 reported no significant 
difference in a standardised pain outcome 
between the monotherapy and combina-
tion therapy groups: however, it is unclear 
whether these results can be generalised.
n	 NON-PhaRMaCOlOgICal  
 TReaTMeNT Of Ra-RelaTeD  
 PaIN
Non-pharmacological pain management 
can be important because chronic pain ac-
ceptance, coping skills and self-efficacy 
contribute to the quality of life of RA pa-
tients, and psychological interventions 
such as cognitive behavioural therapy may 
also help (95-98). A better understanding 
of pain mechanisms can limit catastrophic 
thoughts concerning the meaning of pain, 
and combined psychological and pharma-
cological strategies can facilitate pain con-
trol. In some cases cognitive therapy may 
be an effective treatment for RA and need 
not necessarily include behavioral strate-
gies (99, 100).
Patients with RA who have moderate dis-
ease activity and limited joint erosions may 
benefit from short-term exercise includ-
ing aerobic capacity and dynamic strength 
training. Short-term, land-based aerobic 
exercise is likely to improve aerobic capac-
ity immediately following the intervention 
but may not affect muscle strength or func-
tional ability. Short-term and long-term, 
land-based aerobic and strength training 
may improve aerobic capacity and muscle 
strength. Exercise also does not appear to 
produce any negative effects with respect 
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to increased pain or disease activity (101).
Resistance exercise in RA is safe, and the 
improvement in most outcomes was statis-
tically significant and possibly clinically 
relevant for RA pain and disability (102). 
In the case of patients with severe, unremit-
ting pain localised to a single joint, joint 
replacement surgery can offer substantial 
relief (103-105). The underlying reasons 
for this are not fully understood, but may 
include the physical protection of subchon-
dral nerves or the avoidance of the devel-
opment of synovitis from an origin in the 
articular cartilage. 
n	 CONClUsIONs
Rheumatoid arthritis is a frequent and 
chronic painful condition affecting the 
synovial joints. Current treatments con-
centrate on suppressing inflammation, but 
rarely provide complete pain relief. Pain 
is not only an important outcome for RA 
patients, but also aggravates disability and 
psychological distress. RA-related pain 
may be mediated by mechanisms such as 
inflammation, structural damage or altered 
central pain processing, and a better un-
derstanding of the different contributions 
of these mechanisms should lead to more 
effective treatment targeting as well as the 
development of new and more efficacious 
treatments with fewer side effects. The 
two most important advances in the treat-
ment of arthritic pain over the last 40 years 
have been the introduction of total joint 
replacement surgery into routine clinical 
practice, and the more recent develop-
ment of biological therapies that suppress 
the underlying inflammatory disease (1, 
2). Both have improved the quality of life 
of large numbers of patients, but both are 
now associated with substantial healthcare 
expenditure. Furthermore, 15% of the pa-
tients undergoing total knee replacement 
surgery may continue to experience per-
sistent and disabling pain, and up to 25% 
of those receiving anti-TNF therapy for 
presumed active RA receive no meaningful 
benefit. RA treatments targeting inflamma-
tory mechanisms not only relieve pain by 
suppressing synovitis, but may also reduce 
central sensitisation by modulating neuro-
immune interactions in the central nervous 
system: they should therefore be offered 
together with pharmacological and non-
pharmacological treatments for RA-related 
pain in order to optimise both short- and 
long-term outcomes (106).
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